Apogee Therapeutics, Inc. (NASDAQ:APGE) Poised To Extend Rally On Strong Momentum

Momentum indicators and moving-average structure favor continued upside in the near term, while fundamental losses and negative cash flow keep valuation elevated. Technical strength points toward further price discovery, balanced by fundamental constraints on long-term valuation.

Recent News

March 2, 2026 — Company issued a business update and pipeline progress alongside its annual report and related disclosures. March 22, 2026 — Management announced upcoming investor engagements and reiterated near-term clinical milestones for APG777 and combination programs. February 17, 2026 (reported Feb 22) — Perceptive Advisors disclosed a meaningful increase in its stake, signaling institutional accumulation.

Technical Analysis

ADX / DI+ / DI-: ADX sits at 26.28, indicating a strong underlying trend; DI+ at 27.58 shows a peak-and-reversal, which reads as a bearish shift in directional pressure even as DI- at 14.31 continues decreasing, a bullish sign for directional balance. Together, strength without clear DI dominance suggests near-term trend continuation is possible but with elevated sensitivity to reversals.

MACD: MACD equals 4.01 with a rising trend and sits above its signal line at 3.26; that cross-above represents a bullish momentum confirmation that supports further upside in the near term.

MRO (Momentum/Regression Oscillator): MRO at 37.77 with a peak-and-reversal indicates the price presently trades above target and carries mean-reversion pressure, implying upside momentum may face pullback risk toward modeled targets.

RSI: RSI at 59.71 and increasing signals strengthening buying pressure without reaching overbought territory, aligning with a continuation-biased short-term price path.

Price vs Moving Averages & Band Structure: Last close $90.55 trades above the 12-day EMA ($85.51), 26-day EMA ($81.18), 20-day average ($84.83), 50-day average ($74.27) and 200-day average ($59.26), reinforcing a bullish price structure; the close sits above the 1× Bollinger upper band ($88.85) and below the 2× band ($92.88), which signals price extension but not extreme divergence. Ichimoku components (Tenkan $83.49, Kijun $77.95, Senkou A $68.63, Senkou B $72.45) place price above the cloud, consistent with trend continuation and available support near $80.36 (super trend lower).

Volume and Volatility: Daily volume (661,135) slightly exceeds the 10-day average (620,404) but remains below longer-term averages; 42-day beta 1.76 and 52-week beta 1.35 indicate above-market sensitivity, so momentum-driven moves can accelerate both directions.

 


Fundamental Analysis

Profitability & Cash Flow: EBIT equals -$78.06M, EBITDA -$77.65M and net income -$69.39M; operating cash flow -$68.14M and free cash flow -$62.75M reflect ongoing cash burn despite positive free cash growth of 15.66% year-over-year. Cash and short-term investments total $730.19M, producing a cash ratio of 26.17 and a current ratio of 26.57, indicating substantial near-term liquidity relative to current liabilities of $27.91M.

Earnings Per Share: Reported EPS equals -$1.03 versus an estimate of -$1.04, delivering a positive EPS surprise of approximately 0.96%, a minor beat that modestly improves near-term sentiment but leaves profitability negative.

Valuation Multiples: P/B stands at 5.23, broadly in line with the industry peer mean of 5.22 and below the industry peer median of 6.16. Reported P/E sits negative at -67.05 due to losses; forward P/E also negative at -47.53. PEG equals 9.30 compared with an industry peer mean of -1.08 and median of -2.28, indicating the company’s forward growth-adjusted multiple reads materially above peer central tendencies.

Capital Structure & Returns: Total equity equals $903.88M with total debt $8.85M (debt-to-equity ≈ 0.0098), showing a low leverage profile. Return on assets -8.88% and return on equity -7.68% remain negative, reflecting continued investment in R&D ($58.44M) and development-stage costs rather than current profitability.

Valuation Conclusion: WMDST values the stock as over-valued, driven by negative earnings, negative free cash flow, and elevated growth-adjusted multiples despite a strong cash position and low leverage that reduce near-term solvency risk.

MOST-RECENT QUARTERLY REPORT
REPORT PERIOD ENDING: 2025-12-31
REPORT DATE: 2026-03-02
NEXT REPORT DATE: 2026-06-01
CASH FLOW  Begin Period Cash Flow 107.9 M
 Operating Cash Flow -68.14 M
 Capital Expenditures -62.00 K
 Change In Working Capital -4.86 M
 Dividends Paid
 Cash Flow Delta 23.6 M
 End Period Cash Flow 131.5 M
 
INCOME STATEMENT REVENUE
 Total Revenue
 Forward Revenue
COSTS
 Cost Of Revenue
 Depreciation 406.0 K
 Depreciation and Amortization 406.0 K
 Research and Development 58.4 M
 Total Operating Expenses 78.1 M
PROFITABILITY
 Gross Profit
 EBITDA -77.65 M
 EBIT -78.06 M
 Operating Income -78.06 M
 Interest Income 8.7 M
 Interest Expense
 Net Interest Income 8.7 M
 Income Before Tax -69.33 M
 Tax Provision 62.0 K
 Tax Rate 21.0 %
 Net Income -69.39 M
 Net Income From Continuing Operations -69.39 M
EARNINGS
 EPS Estimate -1.04
 EPS Actual -1.03
 EPS Difference 0.01
 EPS Surprise 0.962 %
 Forward EPS -1.36
 
BALANCE SHEET ASSETS
 Total Assets 937.1 M
 Intangible Assets
 Net Tangible Assets 903.9 M
 Total Current Assets 741.4 M
 Cash and Short-Term Investments 730.2 M
 Cash 131.5 M
 Net Receivables
 Inventory
 Long-Term Investments 8.7 M
LIABILITIES
 Accounts Payable 1.2 M
 Short-Term Debt
 Total Current Liabilities 27.9 M
 Net Debt
 Total Debt 8.8 M
 Total Liabilities 33.3 M
EQUITY
 Total Equity 903.9 M
 Retained Earnings -561.76 M
VALUATION & PER-SHARE METRICS EQUITY & PER-SHARE METRICS
 Book Value Per-Share 13.21
 Shares Outstanding 68.401 M
 Revenue Per-Share
VALUATION
 Market Capitalization 4.7 B
 Enterprise Value 4.0 B
 Enterprise Multiple -51.547
Enterprise Multiple QoQ 59.092 %
Enterprise Multiple YoY 109.12 %
Enterprise Multiple IPRWA high: 67.346
median: 47.169
mean: 12.429
APGE: -51.547
low: -114.076
 EV/R
CAPITAL STRUCTURE
 Asset To Equity 1.037
 Asset To Liability 28.184
 Debt To Capital 0.01
 Debt To Assets 0.009
Debt To Assets QoQ -40.025 %
Debt To Assets YoY -39.834 %
Debt To Assets IPRWA high: 1.032
mean: 0.121
APGE: 0.009
median: 0.003
low: 0.0
 Debt To Equity 0.01
Debt To Equity QoQ -41.726 %
Debt To Equity YoY -15.458 %
Debt To Equity IPRWA high: 1.524
mean: 0.137
APGE: 0.01
median: 0.005
low: -0.893
PRICE-BASED VALUATION
 Price To Book (P/B) 5.226
Price To Book QoQ 8.908 %
Price To Book YoY 124.627 %
Price To Book IPRWA high: 19.432
median: 6.164
APGE: 5.226
mean: 5.215
low: -10.511
 Price To Earnings (P/E) -67.051
Price To Earnings QoQ 59.097 %
Price To Earnings YoY 94.873 %
Price To Earnings IPRWA high: 71.892
mean: -21.078
median: -32.121
APGE: -67.051
low: -107.019
 PE/G Ratio 9.304
 Price To Sales (P/S)
Price To Sales QoQ
Price To Sales YoY
Price To Sales IPRWA
FORWARD MULTIPLES
Forward P/E -47.526
Forward PE/G 6.594
Forward P/S
EFFICIENCY OPERATIONAL
 Operating Leverage
ASSET & SALES
 Asset Turnover Ratio
Asset Turnover Ratio QoQ
Asset Turnover Ratio YoY
Asset Turnover Ratio IPRWA
 Receivables Turnover
Receivables Turnover Ratio QoQ
Receivables Turnover Ratio YoY
Receivables Turnover Ratio IPRWA
 Inventory Turnover
Inventory Turnover Ratio QoQ
Inventory Turnover Ratio YoY
Inventory Turnover Ratio IPRWA
 Days Sales Outstanding (DSO)
CASH CYCLE
 Cash Conversion Cycle Days (CCC)
Cash Conversion Cycle Days QoQ
Cash Conversion Cycle Days YoY
Cash Conversion Cycle Days IPRWA high: 937.301
mean: 220.236
median: 192.562
APGE: 0
low: -594.03
CAPITAL DEPLOYMENT
 Cash Conversion Ratio
 CapEx To Revenue
 CapEx To Depreciation -0.153
 
CAPITAL, LIQUIDITY & COVERAGE CAPITAL STRUCTURE
 Total Capital 903.9 M
 Net Invested Capital 903.9 M
 Invested Capital 903.9 M
 Net Tangible Assets 903.9 M
 Net Working Capital 713.5 M
LIQUIDITY
 Cash Ratio 26.166
 Current Ratio 26.566
Current Ratio QoQ 67.47 %
Current Ratio YoY 43.235 %
Current Ratio IPRWA high: 27.397
APGE: 26.566
mean: 3.874
median: 2.827
low: 0.027
 Quick Ratio
Quick Ratio QoQ
Quick Ratio YoY
Quick Ratio IPRWA
COVERAGE & LEVERAGE
 Debt To EBITDA -0.114
 Cost Of Debt 0.084 %
 Interest Coverage Ratio -7805.6
Interest Coverage Ratio QoQ 9.509 %
Interest Coverage Ratio YoY 2.866 %
Interest Coverage Ratio IPRWA high: 671.002
mean: 40.497
median: 3.11
low: -1571.333
APGE: -7805.6
 Operating Cash Flow Ratio -2.442
TIMING / LIQUIDITY
 Days Payables Outstanding (DPO)
DIVIDENDS
 Dividend Coverage Ratio
 Dividend Payout Ratio
 Dividend Rate
 Dividend Yield
PERFORMANCE GROWTH
 Asset Growth Rate 49.664 %
 Revenue Growth
Revenue Growth QoQ
Revenue Growth YoY
Revenue Growth IPRWA
 Earnings Growth -7.207 %
Earnings Growth QoQ 307.175 %
Earnings Growth YoY -118.782 %
Earnings Growth IPRWA high: 204.0 %
APGE: -7.207 %
median: -14.286 %
mean: -16.965 %
low: -237.5 %
MARGINS
 Gross Margin
Gross Margin QoQ
Gross Margin YoY
Gross Margin IPRWA
 EBIT Margin
EBIT Margin QoQ
EBIT Margin YoY
EBIT Margin IPRWA
 Return On Sales (ROS)
Return On Sales QoQ
Return On Sales YoY
Return On Sales IPRWA
CASH FLOW
 Free Cash Flow (FCF) -62.75 M
 Free Cash Flow Yield -1.328 %
Free Cash Flow Yield QoQ -31.12 %
Free Cash Flow Yield YoY -53.371 %
Free Cash Flow Yield IPRWA high: 21.452 %
median: 0.303 %
mean: 0.161 %
APGE: -1.328 %
low: -51.848 %
 Free Cash Growth 15.659 %
Free Cash Growth QoQ -215.114 %
Free Cash Growth YoY -72.271 %
Free Cash Growth IPRWA high: 177.21 %
APGE: 15.659 %
median: -24.526 %
mean: -33.041 %
low: -201.25 %
 Free Cash To Net Income 0.904
 Cash Flow Margin
 Cash Flow To Earnings 0.982
VALUE & RETURNS
 Economic Value Added 0.04
 Return On Assets (ROA) -8.877 %
Return On Assets QoQ -12.352 %
Return On Assets YoY 1.047 %
Return On Assets IPRWA high: 33.814 %
median: 1.099 %
mean: -2.696 %
APGE: -8.877 %
low: -65.985 %
 Return On Capital Employed (ROCE) -8.585 %
 Return On Equity (ROE) -0.077
Return On Equity QoQ -30.769 %
Return On Equity YoY 16.707 %
Return On Equity IPRWA high: 0.809
median: 0.039
mean: 0.001
APGE: -0.077
low: -1.16
 DuPont ROE
 Return On Invested Capital (ROIC) -6.822 %
Return On Invested Capital QoQ -28.967 %
Return On Invested Capital YoY -145.745 %
Return On Invested Capital IPRWA high: 50.944 %
median: 3.016 %
mean: -0.102 %
APGE: -6.822 %
low: -58.737 %

Six-Week Outlook

Momentum indicators and price structure favor additional upside over the next six weeks, with MACD above its signal line and the price above short- and long-term averages supporting continuation. MRO above zero and a peak-and-reversal characteristic signal probability of intermittent pullbacks; key technical support resides near the super trend lower at $80.36 and the 20-day average near $84.83. Upside first-phase reference lies between the recent close and the mean price target near $101.25, while two-way volatility and elevated betas indicate faster moves than the broader market. Traders should monitor MACD momentum and MRO reversion signals for shifts in near-term bias and consider liquidity metrics and upcoming clinical milestones in fundamental context when assessing risk exposure.

About Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc. (NASDAQ:APGE) focuses on developing biologic therapies for inflammatory and immunological disorders. Based in Waltham, Massachusetts, Apogee Therapeutics seeks to address conditions such as atopic dermatitis, asthma, and chronic obstructive pulmonary disease through innovative solutions. The company concentrates on the development of subcutaneous extended half-life monoclonal antibodies, including APG777 and APG808, which aim to provide prolonged relief for patients by reducing the frequency of dosing and enhancing therapeutic outcomes. Apogee Therapeutics also advances early-stage programs like APG990 and APG222, targeting atopic dermatitis with the potential to improve standard care practices. Through its dedication to scientific research and development, Apogee Therapeutics endeavors to address unmet medical needs and improve patient quality of life.



© 2026 WMDST — The World’s Most Dangerous Swing Trader. All rights reserved.